HOME >> MEDICINE >> NEWS
Higher doses of cancer drug imatinib proven effective and safe

ortance as previous studies of another cancer drug (interferon alpha) have shown that CCR is associated with a 70 to 80 percent chance of 10-year survival, a positive prospect as the survival time for newly diagnosed CML patients is typically about five years.

Another measure of successful treatment is the number of patients with complete molecular response, occurring when the levels of BCR-ABL are so low that they are undetectable using a highly sensitive method called polymerase chain reaction. In past studies, patients who had undetectable levels of BCR-ABL after treatment have not relapsed after long-term follow up. In high-dose therapy patients, the incidence of complete molecular response was 28 percent compared to only seven percent of patients taking the standard dosage of imatinib.

"The high rates of complete cytogenetic and molecular response that we've seen in this study are unprecedented. If such responses have similar long-term significance as seen in previous studies, this translates into a major improvement in the prognosis of patients with CML," states Hagop Kantarjian, M.D., chairman of the Department of Leukemia at M. D. Anderson Cancer Center and the lead author of the study.

Researchers found that the high dosage of imatinib was generally well tolerated, with a similar rate of side effects as standard dose imatinib. To reduce more severe side effects, the dosage of imatinib was lowered to 600 mg or 400 mg daily for some patients, though a majority remained at the target dosage.

The disease did not transform beyond the chronic phrase in any of the study patients, and 98 percent had a complete hematologic response, meaning the number of white blood cells was no longer out of control and the signs and symptoms of leukemia were gone.

The results of the study indicate that patients in the early stage of this cancer may benefit from higher doses of the drug imatinib in their initial treatment to safely and effe
'"/>

Contact: Aislinn Raedy
araedy@hematology.org
202-776-0544
American Society of Hematology
1-Apr-2004


Page: 1 2 3

Related medicine news :

1. Higher folate intake associated with decreased risk of hypertension in women
2. Higher incidence of rejection following early steroid withdrawal
3. Higher radiation doses help some lung cancer patients live longer
4. Higher dose of Gleevec leads to increased remission in CML patients
5. Higher education or larger brain size may protect against dementia later in life, new study finds
6. Higher cost sharing reduces plans drug expenditures, but boosts enrollee costs
7. Higher nocturnal blood pressure predictive of kidney disease in diabetes
8. First quarter 2002 prescription drug spending: Higher again, but rate of increase drops
9. Higher rate of improvement, lower rate of adverse effects with clarithromycin for acute exacerbations of chronic bronchitis
10. Cancer Rates In Children Of Nuclear Industry Employees No Higher Than General Population In England And Wales
11. New Study Finds Blacks Face 38 Percent Higher Stroke Risk

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... December 07, 2016 , ... Augustine Insurance Agency, a ... and business owners in the greater Dallas metropolitan area, is announcing a charity ... Foundation. , Established in 2009 by active police professionals in the Dallas region, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the nationally ... Your Health on Voice of America, declared on her radio program in November 2016 ... fact that when these bullies attack leaders in corporate America, they are trying to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live From won ... year’s best in pioneering, inventive, and ultimately successful projects undertaken by the media ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, LA.c., ... Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of experience ... to help patients realize their family building goals. Acupuncture helps fertility patients ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma Alliance ( ... cavernous angiomas, was awarded a grant from the Julian Grace Foundation to increase ... has more people with cavernous angioma than anywhere in the world. Most share ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  Alopexx Oncology, LLC ... a recombinant antibody fusion protein (immunocytokine) composed of interleukin-2 ... the same target on B cells as Rituxan and ... components but is also involved in tumor targeting, engagement ... vaccine effect. The results of the study (abstract #95954) ...
(Date:12/6/2016)... 2016 Homozygous Familial Hypercholesterolemia (HoFH) ... Global Markets Direct,s latest Pharmaceutical and ... (HoFH) – Pipeline Review, H2 2016, provides ... (HoFH) (Metabolic Disorders) pipeline landscape. Homozygous ... is caused due to mutation from both ...
(Date:12/6/2016)... CENTENNIAL, Colo. , Dec. 6, 2016 /PRNewswire-USNewswire/ ... providers of cartilage, cellular, bone, skin and soft-tissue ... Kimberly Meyer , Business Process Manager, for being ... 2016 Malcolm Baldrige National Quality Award by the ... (NIST), deepening the organization,s commitment to process excellence. ...
Breaking Medicine Technology:
Cached News: